Diabetic Peripheral Neuropathy. Type 2 diabetes mellitus with diabetic neuropathy, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Three months before the start of treatment, patients will be asked to discontinue all their analgesics and receive gabapentin 400-300 milligrams per day. If the sym
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: patients type I or II diabetes mellitus, with diabetic neuropathic pain Resistant to usual drug treatments, at least for 6 months Minimum Pain Rating 4 based on Numerical Rating Having normal creatinine and CBC blood counts HBA1C less than 8%.
Exclusion criteria
Exclusion criteria: Having a pacemaker or defibrillator Having brain stimulators Infection or inflammation at the site of electrodes Other neuropathies with causes other than diabetes Alcohol consumption history Malignant history Tens Records history Pregnancy Bipolar patients Duloxetine contraindications such as liver or kidney failure and MAO-I simultaneous use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain caused by diabetic peripheral neuropathy. Timepoint: Before starting treatment, 1 month and 3 months after starting treatment. Method of measurement: Patients will be assessed based on NRS (Numerical Rating Scale). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Bahram Naderi Nabi
Rasht University of Medical Sciences
Outcome results
None listed